Research Article

Antiproliferative Activity of *T. welwitschii* Extract on Jurkat T Cells *In Vitro*

Batanai Moyo and Stanley Mukanganyama

Biomolecular Interactions Analyses Laboratory, Department of Biochemistry, University of Zimbabwe, P.O. Box MP 167, Mount Pleasant, Harare, Zimbabwe

Correspondence should be addressed to Stanley Mukanganyama; smukanganyama@medic.uz.ac.zw

Received 6 July 2015; Revised 2 September 2015; Accepted 3 September 2015

Academic Editor: Kodappully Sivaraman Siveen

Copyright © 2015 B. Moyo and S. Mukanganyama. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Triumfetta welwitschii is a plant used traditionally for the treatment of fever and diarrhoea. Previous work has shown that *T. welwitschii* has antibacterial activity. The purpose of this study was to investigate *T. welwitschii* extract for anticancer activity against Jurkat T cells. The Jurkat T cell line is used to study acute T cell leukaemia. An antiproliferation assay, determination of induction of apoptosis, the determination of the effect of the combination of the extract and GSH, and effects of the extract on DNA leakage were conducted. *T. welwitschii* was found to decrease cell viability in a dose- and time-dependent manner. *T. welwitschii* caused apoptosis in the Jurkat T cells as shown by DNA fragmentation. When *T. welwitschii* was combined with reduced GSH, it was found that the growth of the Jurkat T cells was significantly reduced compared to untreated cells after 72 h of treatment. This was unexpected, as cancer cells have elevated levels of GSH compared to normal cells. The results of this study show that *T. welwitschii* is a potential source of compounds that may serve as leads for anticancer compounds.

1. Introduction

Cancer is a leading cause of death worldwide, accounting for 13% of all deaths worldwide in 2008 [1]. In developing countries, cancer is the third leading cause of death after infectious and cardiovascular diseases [2]. According to the World Health Organisation, there may be 21.4 million cases of cancer and 13.2 million deaths from cancer annually by 2030 [3]. Genetic and molecular modifications such as transformation, deregulation of apoptosis, proliferation, invasion angiogenesis, and metastasis are characteristics of cancer [4].

Leukaemia is a type of cancer where white blood cells and their precursors multiply and differentiate abnormally, resulting in a decrease in the production and function of normal cells [5]. Generally, chemotherapy, surgery, and radiation are the standard modes of treatment of cancer [3]; however, some of these procedures have been associated with side effects and drug resistance, particularly at high doses. Given that leukaemia is a systemic disease, its treatment and cure depends on chemotherapy rather than surgery [6].

Chemotherapy, radiation, immunotherapy, stem cell transplants, targeted therapy, and splenectomies are examples of standard leukaemia treatments [7].

The use of natural plant products such as plant extracts may reduce the side effects associated with cancer treatment [8]. The large number of components in the plants may overcome limitations of chemo- and targeted therapies, showing great anticancer potential [9]. A variety of compounds can be used as starting points for the synthesis of new drugs with improved activity [10]. Between 1983 and 1994, 60% of approved anticancer drugs were from natural sources [11]. A water extract of green tea leaves was recently approved for use as a drug by the Food and Drug Administration (FDA), proving that plant products can meet the high standards required by the FDA [4].

Plant compounds used in traditional medicine are generally considered safe as they are usually consumed as part of the diet [9]. An increase in the consumption of fruits, vegetables, whole grains, and spices has been seen to result in a decrease of the number of incidences of various types of cancer [5, 8, 9]. Plants contain natural compounds such as

polyphenols that are known to reduce the risk of diseases such as cancer, diabetes, and neurodegenerative diseases [12].

Plant products, thus, play a large role in cancer prevention and, as documented in other studies, serve as a source of drugs [13]. Several studies conducted have shown that some plant extracts have anticancer activity [4, 14–18]. An example of a cancer drug from a plant is paclitaxel from *Taxus brevifolia*, which is also known as the northwest Pacific Yew tree [19]. Although most cancer drugs currently in use were isolated from plants, some of them have been shown to have side effects. The observed side effects are possibly due to the fact that single, pure compounds are used. A whole extract is expected to reduce or completely avoid the side effects.

T. welwitschii var. *welwitschii* is a shrubby plant that grows in Africa. *T. welwitschii* is used traditionally for the treatment of diarrhoea [20] and fever [21]. Fever is a symptom of inflammation, and chronic inflammation has been linked to cancer in some cases [22]. We have shown that *T. welwitschii* has antibacterial activity (unpublished results).

The aim of this study was to determine the effects of *T. welwitschii* var. *welwitschii* extract on Jurkat T cells. Jurkat T cells are a cell line used to study acute T cell leukaemia, T cell signalling [23], and the expression of various chemokines.

2. Materials and Methods

2.1. Chemicals. All chemicals, sera, media, and drugs used were purchased from Sigma-Aldrich (Steinheim, Germany) and were of analytical grade. These included foetal bovine serum (FBS), Roswell Park Memorial Institute 1640 media (RPMI), reduced L-glutathione (GSH), penicillin, neomycin, and streptomycin solution (PNS), Hanks Buffered Saline Solution (HBSS), methanol, dimethyl sulfoxide (DMSO), agarose, ethidium bromide (EtBr), Trypan blue dye, monochlorobimane (MCB), 2-4 dinitrochlorobenzene, and doxorubicin.

2.2. Plant Material. *Triumfetta welwitschii* var. *welwitschii* was collected from Centenary, Mashonaland Central, Zimbabwe (16.8°S, 31.1167°E, and 1156 m above sea level), and identified by Mr. Christopher Chapano of the Harare Botanical Gardens, Zimbabwe. Dried roots were ground to a fine powder using a blender (Philips Co., Shanghai, China). Herbarium samples were stored in the Biomolecular Interactions Analysis Laboratory (BIA) Herbarium, University of Zimbabwe. Methanol was used for the extraction of compounds. To 20 g of powder, 200 mL of methanol was added. After 20 min, the plant extract was filtered using Whatmann number 1 filter paper and then dried under a stream of air until the methanol had evaporated. To prepare the extract solutions for testing, the plant extract was dissolved in DMSO and RPMI media, so that the final concentration of DMSO when added to test well was 0.83%. DMSO at a concentration of 0.83% was not found to be toxic to the Jurkat T cells.

2.3. Jurkat T Cells. Jurkat E6.1 human leukaemic T cell lymphoblasts (Jurkat T cells) were obtained from the European Collection of Cell Cultures (ECACC) (Salisbury, UK). They

were grown in RPMI-1640 media supplemented with 10% FBS and 1% PNS solution at 37°C with 5% CO₂ in an incubator (Shellab CO₂ Series, Sheldon Mfg. Inc., Cornelius, USA).

2.4. Antiproliferation Assay. *T. welwitschii* root methanol extracts at 0, 31.25, 62.5, 125, and 250 µg·mL⁻¹ (final concentration in the wells) were used. Doxorubicin (10 µg·mL⁻¹) was used as the positive control. To each well in a 12-well plate, 100 µL of the plant extract or doxorubicin was added. The number of cells added to each well was 1 × 10⁵ cells·mL⁻¹. The volume was brought to 3 mL by adding RPMI. The plates were incubated at 37°C and 5% CO₂ for 72 h (Shellab CO₂ Series, Sheldon Mfg. Inc., Cornelius, USA). Every 24 h, 100 µL of cells was collected to count the number of cells in each well. To the 100 µL of cells, 50 µL of 0.4% Trypan blue was added before counting the number of cells using a microscope. The dead cells were stained blue while the live cells were not stained.

2.5. Determination of Induction of Apoptosis. Jurkat T cells were treated with *T. welwitschii* extracts at 31.25, 62.5, 125, and 250 µg·mL⁻¹ for 72 h before being used for this experiment. Cells treated with doxorubicin at 10 µg·mL⁻¹ and the vehicle control (DMSO) only were used as the positive and negative controls, respectively. The cells were centrifuged at 12 000 rpm for 5 min in a KK Centrifuge (Gemmy Industrial Corp., Taiwan) and then washed with PBS (pH 7.2). After discarding the supernatant, 200 µL of lysis solution (10 mM Tris (pH 7.4), 5 mM EDTA, 0.2% Triton X-100) and 10 µL of 1 mg·mL⁻¹ proteinase K were added. The cells were left in a 56°C water bath overnight (Shaker Bath SBS30, Stuart Scientific, UK). Eight microliters of RNAase (100 µg·mL⁻¹) was added to each tube, and then the incubation continued at 37°C for 1 hour. Twenty microliters of 1.5 M NaCl was added, and then the tubes were inverted several times before being centrifuged at 12 000 rpm for 15 min. The supernatant was added to clean eppendorf tubes. Ice cold isopropyl alcohol (2x the volume) was added. The tubes were inverted several times and left at -80°C for 1 h. The tubes were centrifuged at 12 000 rpm for 15 min in a microcentrifuge (Centrifuge 5415C, Eppendorf, Berlin, Germany), and the supernatant was then discarded. The isolated DNA was allowed to air-dry before being resuspended in TE buffer (10 mM Tris-HCl (pH 7.4) and 0.5 mM EDTA).

Gel electrophoresis was conducted using a BioRad electrophoresis unit (BioRad, Hercules, USA). A gel was prepared using 1 g agarose and 100 mL of TAE buffer. Ethidium bromide (0.5 µg·mL⁻¹) was added to the gel before pouring. Loading buffer (12.5 mg bromophenol blue and 2 g sucrose in 5 mL distilled water) was added to each sample and constituted 1/5 of the total volume. Ten microliters of sample was added to the wells except in lanes 1, 9, and 10 where 5 µL was used. A Thermo Scientific GeneRuler 100 bp Plus DNA Ladder was also run. Five microliters of the ladder was loaded onto the gel. The gel was run at 110 V until the dye had travelled down 80% of the length of the gel. The gel was observed under UV light and photographed (MiniBIS

BioImaging System, Dnr BioImaging Systems, Jerusalem, Israel).

2.6. Effect of Reduced Glutathione on the Action of *T. welwitschii*. Glutathione is involved in maintaining a redox balance in cells, thus protecting cells from damage due to oxidative stress [9]. Thus, the effect of reduced glutathione (GSH) on the activity of *T. welwitschii* root methanol extract was investigated. This assay was conducted to determine if the GSH antagonises or enhances the effect of the plant extract on the cancer cells. To a 12-well plate, the following samples were added in triplicate: cells and media; cells, media, and GSH; cells, *T. welwitschii* root methanol extract, and media; cells, *T. welwitschii* root methanol extract, GSH, and media. The concentration of GSH used was $25 \mu\text{g}\cdot\text{mL}^{-1}$ and that of the plant extract used was $19 \mu\text{g}\cdot\text{mL}^{-1}$ (the IC_{50}). The plates were incubated at 37°C with 5% CO_2 for 72 hours. The Trypan blue dye exclusion method was used to count the cells using a microscope.

2.7. Determination of the Effect of *T. welwitschii* and Doxorubicin on Jurkat T Cells Using the Propidium Iodide Assay. The effect of *T. welwitschii* and doxorubicin on Jurkat T cells was analysed using propidium iodide. The assay was conducted according to the method described by Kelter et al. [24] with some modifications. Propidium iodide is capable of binding to the DNA in nonviable cells after passing through damaged membranes [24]. Cells at a density of 1×10^4 cells $\cdot\text{mL}^{-1}$ were added to a 96-well plate and incubated overnight at 37°C , 5% CO_2 . Control wells containing media only were also prepared. After the overnight incubation, *T. welwitschii* and doxorubicin were added to wells in triplicate. The concentrations ranged from 0 to $200 \mu\text{g}\cdot\text{mL}^{-1}$ for *T. welwitschii* and from 0 to $8 \mu\text{g}\cdot\text{mL}^{-1}$ for doxorubicin. *T. welwitschii* and doxorubicin were also added to wells containing media only. The plates were incubated for 4 days. The media were aspirated from the wells, and then $7 \mu\text{g}\cdot\text{mL}^{-1}$ propidium iodide was added to each well. Fluorescence was measured at an excitation wavelength of 544 nm and an emission wavelength of 612 nm using a f_{max} microplate spectrofluorometer (Molecular Devices, Sunnyvale, USA). The plates were frozen to kill all of the cells and then thawed before fluorescence was measured as before. Growth stimulation/inhibition was calculated as $\text{T/C} \times 100\%$, where T and C are the fluorescence readings of the test and control samples, respectively. $\text{T/C} > 125\%$ indicated stimulation, while $\text{T/C} < 30\%$ indicated cytotoxicity.

2.8. Determination of the Effect of *T. welwitschii* on Drug Efflux in Jurkat T Cells. Drug efflux is a mechanism of drug resistance in cancer cells [25]. The purpose of this assay was to determine if *T. welwitschii* root methanol extract is capable of blocking the efflux pumps in Jurkat T cells. Cells at a density of 2×10^6 cells $\cdot\text{mL}^{-1}$ were washed in Hank's buffered salt solution (HBSS) and centrifuged at 2000 rpm for 5 minutes. The pellet was resuspended in ice-cold HBSS containing 10 mM HEPES (pH 7.4) and centrifuged at 2000 rpm for 5 min. HBSS containing $5 \mu\text{M}$ monochlorobimane (MCB) was added to

the cells, which were then incubated for 1 hr in a waterbath at 10°C . The cells were washed twice in HBSS containing 11.1 mM glucose. After washing, the cells, resuspended in HBSS with glucose, were divided equally between six tubes, each with an equal concentration of cells. Two tubes served as an untreated control. To two tubes *T. welwitschii* was added at a concentration of $10 \mu\text{g}\cdot\text{mL}^{-1}$ (enough to have an effect but not to kill the cells), and to the last two tubes, CDNB was used as the positive control at 1 mM. CDNB reacts with glutathione to form 2,4-dinitrophenylglutathione. This product is pumped out of the cell via efflux pumping and therefore will complete with glutathione-bimane [26]. The samples were incubated for 1 hr at 37°C and then centrifuged at 2000 rpm for 5 min. The supernatant was collected. The fluorescence of the plates was measured at 390 nm and 510 nm (excitation and emission, resp.) using a f_{max} microplate spectrofluorometer (Molecular Devices, Sunnyvale, USA).

2.9. Statistical Analysis. GraphPad Prism 5 for Windows (GraphPad Software Inc., San Diego, California, USA) version 5.03 was used to analyse the results using one-way analysis of variance test (ANOVA) with Dunnett's Multiple Comparison Test. Values with a *P* value 0.05 or less were considered statistically significant.

3. Results

3.1. Antiproliferation Assay. The results of the antiproliferation assay are shown in Figure 1. The most rapid growth of the untreated cells was observed between 48 h and 72 h, where the cell viability increased from 33.2% to 100%. As the concentration of the plant extract increased, the percentage of live cells decreased. Cells treated with $250 \mu\text{g}\cdot\text{mL}^{-1}$ *T. welwitschii* had viabilities of less than 0.5%. Cells treated with doxorubicin did not survive treatment. When the cells were treated with $31.25 \mu\text{g}\cdot\text{mL}^{-1}$ and $62.5 \mu\text{g}\cdot\text{mL}^{-1}$ of the extract, the percentage of live cells increased over 72 h but did not rise above 19.38% ($31.25 \mu\text{g}\cdot\text{mL}^{-1}$). At $125 \mu\text{g}\cdot\text{mL}^{-1}$ and $250 \mu\text{g}\cdot\text{mL}^{-1}$ of plant extract, the cell viability decreased with time. Doxorubicin was used at a concentration of $10 \mu\text{g}\cdot\text{mL}^{-1}$ and was found to have growth inhibition activity against the Jurkat T cells. At 24 h, cell viability was 2.1% but decreased to 0.1% at 72 h.

3.2. Determination of Induction of Apoptosis. The results of this assay are shown in Figure 2. The photograph of the gel shows DNA laddering caused by doxorubicin and *T. welwitschii* at various concentrations. A 1 kb pair marker was run in lane 10 to measure the bands. A large band signifying intact DNA was observed in the lanes containing untreated cells (lanes 6 and 9). More DNA fragmentation was observed in the cells treated with *T. welwitschii* than those treated with doxorubicin. The sizes of the bands ranged from larger than 3000 bp to smaller than 100 bp. Small (<100 bp) fragments were observed in the untreated cells. Some DNA in all of the lanes except the one with the marker failed to migrate from the wells. The bands appeared as smears as they tended to run into each other.

FIGURE 1: Percentage surviving cells after exposure to *T. welwitschii* and doxorubicin for 24, 48, and 72 h. The number of live negative control cells ($0 \mu\text{g}\cdot\text{mL}^{-1}$) at 72 h was used as 100%, so all cells were expressed as a percentage of them. Values indicate the mean $\pm$ SD for $n = 3$. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

3.3. Effect of Reduced Glutathione on the Activity of *T. welwitschii*. Figure 3 shows the effect of GSH on the activity of *T. welwitschii* root methanol extract against Jurkat T cells. The extract showed dose-dependent activity against the Jurkat T cells. The growth of cells was 36.9% at 24 h, 38.3% at 48 h, and 40% at 72 h. GSH did not cause any significant changes in the growth of cells at 72 h. Combining the extract with GSH resulted in increased growth of the Jurkat T cells compared to the extract alone. When GSH was combined with doxorubicin, cell growth increased slightly at 24 h and 48 h compared to cells treated with doxorubicin only, while at 72 h there were no live cells.

3.4. Effect of *T. welwitschii* on Drug Efflux in Jurkat T Cells. The results of this assay are shown in Figure 4. In the control group, there was slightly more efflux than accumulation (1.6

fluorescence units (F/units) and 1.5 F/units, resp.). Treating the Jurkat T cells with the extract increased efflux of the monochlorobimane-glutathione (MCB-GSH) conjugate from the cancer cells compared to accumulation (5 F/units and 1.6 F/units, resp.). CDNB which is converted to CDNB-GSH caused slightly more accumulation of the MCB-GSH conjugate in the Jurkat T cells than efflux (1.5 F/units and 1.3 F/units, resp.). *T. welwitschii* extract enhanced the efflux of the MCB-GSH conjugate from the Jurkat T cells.

3.5. The Effect of *T. welwitschii* and Doxorubicin on Jurkat T Cells Using Propidium Iodide. The purpose of the propidium iodide assay was to determine the effect of *T. welwitschii* extract and doxorubicin on Jurkat T cells using propidium iodide. Propidium iodide is only capable of entering cells with damaged membranes and binding to their DNA, thus

FIGURE 2: Gel electrophoresis following treatment with *T. welwitschii* extracts at various concentrations. For lanes 2–8, 10 μL was loaded, while for the rest, 5 μL was loaded. The results of the assay show that DNA fragmentation was caused by the Jurkat T cells. Lanes 1, 7: 10 $\mu\text{g}\cdot\text{mL}^{-1}$ doxorubicin (5 μL in lane 1, 10 μL in lane 7). Lanes 2, 3, 4, 5, and 6: *T. welwitschii* 250, 125, 62.5, and 31.25 $\mu\text{g}\cdot\text{mL}^{-1}$. Lane 8: *T. welwitschii* 250 $\mu\text{g}\cdot\text{mL}^{-1}$. Lane 6, 9: 0 $\mu\text{g}\cdot\text{mL}^{-1}$ (5 μL). Lane 10: GeneRuler 100 bp Plus DNA Ladder (5 μL).

making it an excellent tool for measuring cell viability [24]. The results of this assay are shown in Figure 5. It was found that increasing the concentration of *welwitschii* resulted in decreased levels of percentages of live cells. At 3.125 $\mu\text{g}\cdot\text{mL}^{-1}$ *T. welwitschii* the percentage of live cells was 113%. This decreased to 52% at 200 $\mu\text{g}\cdot\text{mL}^{-1}$. There was no difference between 6.25 $\mu\text{g}\cdot\text{mL}^{-1}$ and 12.5 $\mu\text{g}\cdot\text{mL}^{-1}$, in the percentage of live treated cells. At 50 $\mu\text{g}\cdot\text{mL}^{-1}$, 100 $\mu\text{g}\cdot\text{mL}^{-1}$, and 150 $\mu\text{g}\cdot\text{mL}^{-1}$ of *T. welwitschii*, the percentages of live treated cells were similar. Increasing the concentration of doxorubicin decreased the percentage of live cells. The range of percentages of live cells treated with doxorubicin was generally lower than the range for the cells treated with the extract.

4. Discussion

Cancer has become one of the top killer diseases worldwide with the numbers of cases and deaths being expected to increase over the next 15 years [3]. An increase in the incidences of drug resistant cancer and terrible side effects has resulted in a need for new anticancer compounds with diverse modes of action and little to no side effects. As whole extracts contain a variety of compounds, they will most likely have a variety of targets. Plants have been used for centuries to treat a variety of illnesses. It has been reported that eating fruit and drinking fruit juices during the first two years of life resulted in a decrease in the incidences of leukaemia in children under the age of 15 years [27].

In this study, *Triumfetta welwitschii* root methanol extract was tested against Jurkat T cells. *T. welwitschii* inhibited

the growth of Jurkat T cells in a dose-dependent manner. As the concentration of the plant extract increased, the number of live cells decreased. The action of 10 $\mu\text{g}\cdot\text{mL}^{-1}$ doxorubicin was comparable to that of 250 $\mu\text{g}\cdot\text{mL}^{-1}$ of the plant extract. At 31.25 $\mu\text{g}\cdot\text{mL}^{-1}$ *T. welwitschii*, the number of live cells had decreased tremendously compared to the untreated cells, showing that large concentrations of the extract were not needed to inhibit the growth of the cells. The plant extract was very effective against Jurkat T cells. Other studies have found plant extracts to have antiproliferative activity against Jurkat T cells, for example, *Hemidesmus indicus* at concentrations ranging from 0.62 $\text{mg}\cdot\text{mL}^{-1}$ to 1.9 $\text{mg}\cdot\text{mL}^{-1}$ [4]. *Triumfetta rhomboidea* has antitumour activity *in vivo* [28, 29]. *Grewia hirsuta*, a Tiliaceae plant, has been found to have anticancer activity against HepG2 cells by arresting the cell cycle [29].

The low percentage of live cells observed in the treated cells show that the plant extract had effective antiproliferative activity against the Jurkat T cells. The concentration needed to reduce the growth of the Jurkat T cells to 50% was 19 $\mu\text{g}\cdot\text{mL}^{-1}$. This concentration is considered to be very low, as, according to the American National Cancer Institute, a value of 30 $\mu\text{g}\cdot\text{mL}^{-1}$ is the highest IC_{50} that is considered promising when searching for activity in whole extracts [11]. The extract may contain phytochemicals that have potential anticancer properties. When testing the effects of any new compound, on cancer cells, cells are exposed to the compound or extract whilst control cells are not exposed the test compound. Thus, the data produced in our study points to the effects of the extract on exposed compared to cells that were not exposed to the extract. In this regard, our data does not elucidate whether the action of the extract was specific or nonspecific. There is, therefore, a need for further studies to be done on normal cells or control cells such as PBMCs.

The clumping of the cells observed *in vitro* could be a result of toxicity as has been observed in other studies with plant extracts [30]. According to Chung et al., leukaemia cells tend to adhere to each other *in vitro* either spontaneously or in response to mitogens and some drugs [30]. A surface molecule, β -catenin, regulates cell-cell adhesion of leukaemic cells [30].

Apoptosis is used by the body to regulate the proliferation of cells [31]. Consequently, an imbalance or inactivation of pathways that regulate apoptosis can result in the formation of tumours and cancer progression [31]. As DNA cleavage is a sign of apoptosis, the DNA laddering assay was conducted. Exposure to the plant extract caused more DNA damage than doxorubicin, which is known to induce apoptosis. In lanes 6 and 9, the DNA from the untreated cells was added. Large bands of DNA that were smaller than 300 bp were observed indicating intact DNA fragments. The banding pattern between the treated and untreated cells can, however, be distinguished as the treated cells show DNA laddering compared to the large intact band seen with the untreated cells. Previous studies found plant extracts that caused DNA fragmentation in Jurkat T cells, for example, fermented wheat germ extract [32] and *Ziziphus jujuba* [33].

GSH is involved in the maintenance of a balanced redox environment within cells [34]. In this study, the effects of

FIGURE 3: The effects of glutathione on the activity of *T. welwitschii*. Glutathione (GSH) was used at a concentration of $25 \mu\text{g}\cdot\text{mL}^{-1}$, while a concentration of $19 \mu\text{g}\cdot\text{mL}^{-1}$ of *T. welwitschii* root methanol extract (extract) was used in this assay. Doxorubicin (dox) was tested against the Jurkat T cells at $1 \mu\text{g}\cdot\text{mL}^{-1}$ and $0.5 \mu\text{g}\cdot\text{mL}^{-1}$. The cells were incubated over a period of 72 h, and cell counts conducted every 24 h using the Trypan blue exclusion assay. To determine significance, all treatments were compared to cells only. Values indicate the mean $\pm$ SD for $n = 3$. ** $P < 0.01$, *** $P < 0.001$.

GSH on the action of *T. welwitschii* root methanol extract were investigated. When the cells were treated with GSH and the plant extract, the growth of the Jurkat T cells was significantly lower than the untreated cells after 72 h. Compared to the extract alone, when GSH and the plant extract were combined, there was an increase in the number of live cells, but this was still lower than the untreated control. GSH would antagonise the action of the plant extract if the extract acted via a redox mechanism [26]. *T. welwitschii*

may, therefore, not act on the Jurkat T cells via a redox pathway. The plant extract may act through the inhibition of a particular enzyme, physiochemical mechanisms, by targeting the DNA/RNA or by targeting ion channels [35].

When the cells were exposed to GSH alone, no significant increase in cell growth was observed. In other studies, it has been observed that some increase in cell growth was expected as GSH protects against reactive oxygen species, mutagens, and drugs [36]. GSH also plays a role in multidrug

FIGURE 4: The effects the plant extract on the efflux of the MCB-GSH conjugate from Jurkat T cells. The graph shows the effect of *T. welwitschii* root methanol extract at a concentration of 10 µg·mL⁻¹ on the efflux of the MCB-GSH conjugate. CDNB was used as the positive control while the negative control, cells only, was treated with the vehicle control. Values indicate the mean ± SD for $n = 8$. *** $P < 0.001$.

resistance by reacting with drugs spontaneously [36]. Tumour cells have more intracellular GSH than normal cells [37] and the depletion of GSH makes cancer cells more susceptible to reactive oxygen species (ROS) and anticancer agents [36]. GSH has been found to induce cell death in HL-60 leukaemia cells in concentrations ranging from 20 µg·mL⁻¹ to 2 000 µg·mL⁻¹ [38]. Further work needs to be done to determine the mode of action of the *T. welwitschii* extract when combined with GSH. Methanol extracts contain many phytoconstituents, including anthocyanins, saponins, xanthoxylines, lactones, flavones, polyphenols, and tannins [39]. Some of these phytochemicals may form conjugates with glutathione that can potentially inhibit the glutathione-dependent enzymes [26].

Propidium iodide is a fluorescent dye that cannot penetrate live cells and binds to DNA [40]. An increase in the fluorescence of propidium iodide corresponds to an increase in the number of dead cells [24]. The results of the study conducted showed that, on their own, *T. welwitschii* and doxorubicin were not cytotoxic towards the Jurkat T cells as, at all tested concentrations, T/C × 10% is greater than 50%. However, a decrease in the percentage of live treated cells was observed as the concentrations of doxorubicin and *T. welwitschii* increased. The doxorubicin was more effective against the cells as the range of percentages of live treated cells was lower even though the concentrations used were much lower. The results of the antiproliferative assay showed the extract and doxorubicin were cytotoxic against the Jurkat T cells. Although the extract is toxic against the cells, the extract may not damage the integrity of the cell membrane. Propidium iodide is only capable of staining nucleic acids in

FIGURE 5: Effect of *T. welwitschii* and doxorubicin on Jurkat T cells measured using the propidium iodide assay. Jurkat T cells were exposed to the plant extract and doxorubicin alone and in combination before the effect was measured using propidium iodide at excitation and emission wavelengths 544 nm and 612 nm, respectively. The growth of the cells is expressed as test/control × 100%. *T. welwitschii*: 1: 3.125 µg·mL⁻¹; 2: 6.250 µg·mL⁻¹; 3: 12.50 µg·mL⁻¹; 4: 25 µg·mL⁻¹; 5: 50 µg·mL⁻¹; 6: 100 µg·mL⁻¹; 7: 150 µg·mL⁻¹; 8: 200 µg·mL⁻¹. Doxorubicin: 1: 0.25 µg·mL⁻¹; 2: 0.5 µg·mL⁻¹; 3: 1 µg·mL⁻¹; 4: 2 µg·mL⁻¹; 5: 3 µg·mL⁻¹; 6: 4 µg·mL⁻¹; 7: 5 µg·mL⁻¹; 8: 8 µg·mL⁻¹.

cells with damaged membranes [24]. Apoptosis may account for the differences in the results observed between the two assays. Following apoptosis, complete degradation of the nucleic acids may have occurred resulting in no positive results, as there would be no nucleic acids for the propidium iodide to bind to. The Trypan blue dye exclusion counting method may, therefore, be considered more accurate than the propidium iodide assay. The accuracy of the counting method is increased by the ability to visualize live and dead cells. Whilst our results are not conclusive of the apoptotic process in themselves, the presence of DNA ladders and the staining of cells by propidium iodide in cell exposed to the extract as compared to the control give indications to possible mechanism of actions. Propidium iodide is capable of binding to the DNA in nonviable cells after passing through damaged membranes. The loss of membrane integrity, thus, could be ascribed to the exposure to the extract as this was not observed in the control cells. After isolation of active phytoconstituents from the crude extract, more comprehensive apoptotic assays would be required to elucidate the mode of cell death.

Chemotherapy can be rendered ineffective by the development of drug resistance. Decreased drug accumulation within a cell is one of several molecular mechanisms proposed to explain drug resistance [25]. A reduction in drug influx via drug solute carriers or increased drug efflux via ATP-binding cassette efflux pumps contributes to a reduction in drug accumulation [25]. The effect of *T. welwitschii* on drug transport in Jurkat T cells was investigated. In this

assay, CDNB was used as the positive control as CDNB via its glutathione conjugate is an efflux pump inhibitor [26]. It was found that *T. welwitschii* root methanol extract at $10 \mu\text{g}\cdot\text{mL}^{-1}$ stimulated efflux of the MCB-GSH conjugate from the Jurkat T cells. The fluorescence of effluxed MCB-GSH conjugate was much higher than the accumulated one, showing that the plant extract induces the efflux of large amounts of the conjugate. A low concentration of the extract was used to prevent cell death. As the plant concentration increased there was corresponding cytotoxicity observed and, therefore, further studies are needed to determine if the mode of action at higher concentrations could be through inhibition of drug efflux. *Cecropia lyratiloba*, *Panax* spp., *Euphorbia serrulata*, and *Ruta graveolens* are examples of plants that contain compounds with drug efflux inhibitory activity [41].

In summary, the results of this study showed that *T. welwitschii* has antiproliferative activity against Jurkat T cells. The effects of the extract were also shown to be irreversible as the plant extract induced DNA fragmentation. *T. welwitschii* is a potential source of lead compounds for new antileukaemic medicines. Key et al. [42] noted that some nonnutrient chemicals in plants have been found to have anticancer activity *in vitro*. Some of the classes are carotenoids, sulphur-containing compounds, and phytosterols [42]. Several medicinal plants have been found to be toxic to humans, for example, *Ziziphus mucronata* and *Athrixia phyllicoides* [43]. Examples of side effects include diarrhoea, immunotoxicity, embryo/foetal and prenatal toxicity, cardiovascular side effects, and hypersensitivity [43]. At times the toxic effects are only seen at high doses, so low doses are required. For that reason, the testing of *T. welwitschii* root methanol extract against normal human cell lines such as peripheral blood mononuclear cells (PBMCs) and normal mouse fibroblast NIH/373 cells is important in order to determine if the extract is toxic against them to ensure that only leukaemic cells are targeted by the extract. The viability of the PBMCs and NIH/373 cells after exposure to the extract will be determined in future studies.

5. Conclusion

The *Triumfetta welwitschii* extract was shown to have antiproliferative activity against Jurkat T cells and its effects were shown to be irreversible. *T. welwitschii* plant may, thus, serve as a potential source of lead compounds for anticancer compounds.

Disclosure

Batanai Moyo is coauthor.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contribution

Batanai Moyo performed the experiments, analysed and interpreted the data, and wrote the paper. Stanley Mukan-ganyama directed the research, collected the plant material, analysed and interpreted the data, and edited the paper. All authors have read and approved the paper.

Acknowledgments

The authors would like to acknowledge Mr. Christopher Chapano from the Botanic Gardens, Harare, who identified *T. welwitschii* var. *welwitschii*, and support from the International Science Programmes (ISP) through the IPICS-ZIM01 Project from the International Program in the Chemical Sciences (IPICS, Uppsala University, Sweden) and the International Foundation for Science (IFS F/3413-03), Stockholm, Sweden.

References

- [1] World Health Organisation (WHO), "Cancer," 2013, <http://www.who.int/mediacentre/factsheets/fs297/en/>.
- [2] N. F. Tanih and R. N. Ndip, "The acetone extract of *Sclerocarya birrea* (Anacardiaceae) possesses antiproliferative and apoptotic potential against human breast cancer cell lines (MCF-7)," *The Scientific World Journal*, vol. 2013, Article ID 956206, 7 pages, 2013.
- [3] American Cancer Society, *Global Cancer Facts and Figures*, 2nd edition, 2011, <http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/document/acspc-027766.pdf>.
- [4] C. Fimognari, M. Lenzi, L. Ferruzzi et al., "Mitochondrial pathway mediates the anti-leukemic effects of *Hemidesmus indicus*, a promising botanical drug," *PLoS ONE*, vol. 6, no. 6, Article ID e21544, 15 pages, 2011.
- [5] C. Ampasavate, S. Okonogi, and S. Anuchapreeda, "Cytotoxicity of extracts from fruit plants against leukemic cell lines," *African Journal of Pharmacy and Pharmacology*, vol. 4, no. 1, pp. 13–21, 2010.
- [6] E. Shacter, J. A. Williams, R. M. Hinson, S. Sentürker, and Y.-J. Lee, "Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis," *Blood*, vol. 96, no. 1, pp. 307–313, 2000.
- [7] C. E. DeSantis, C. C. Lin, A. B. Mariotto et al., "Cancer treatment and survivorship statistics, 2014," *CA: A Cancer Journal for Clinicians*, vol. 64, no. 4, pp. 252–271, 2014.
- [8] A. González-Sarriás, L. Li, and N. P. Seeram, "Effects of maple (*Acer*) plant part extracts on proliferation, apoptosis and cell cycle arrest of human tumorigenic and non-tumorigenic colon cells," *Phytotherapy Research*, vol. 26, no. 7, pp. 995–1002, 2012.
- [9] N. M. Al-Daghri, M. S. Alokail, K. M. Alkharfy et al., "Fenu-greek extract as an inducer of cellular death via autophagy in human T lymphoma Jurkat cells," *BMC Complementary and Alternative Medicine*, vol. 12, article 202, 2012.
- [10] S. P. Songca, C. Sebothoma, B. B. Samuel, and J. N. Eloff, "A biflavonoid and a carotenoid from *Rhus leptodictya*: isolation, characterization and antibacterial properties," *African Journal of Biochemistry Research*, vol. 6, no. 13, pp. 172–178, 2012.

- [11] V. Kuete, I. K. Voukeng, R. Tsohou et al., "Cytotoxicity of *Elaeophorbia drupifera* and other Cameroonian medicinal plants against drug sensitive and multidrug resistant cancer cells," *BMC Complementary and Alternative Medicine*, vol. 13, article 250, 2013.
- [12] K. B. Pandey and S. I. Rizvi, "Plant polyphenols as dietary antioxidants in human health and disease," *Oxidative Medicine and Cellular Longevity*, vol. 2, no. 5, pp. 270–278, 2009.
- [13] G. M. Cragg and D. J. Newman, "Plants as a source of anti-cancer agents," *Journal of Ethnopharmacology*, vol. 100, no. 1-2, pp. 72–79, 2005.
- [14] R. Fares, S. Bazzi, S. E. Baydoun, and R. M. Abdel-Massih, "The antioxidant and anti-proliferative activity of the lebanese *Olea europaea* extract," *Plant Foods for Human Nutrition*, vol. 66, no. 1, pp. 58–63, 2011.
- [15] M. Khan, R. A. Qureshi, M. Hussain, K. Mehmood, and R. A. Khan, "Hexane soluble extract of *Mallotus philippensis* (Lam.) Muell. Arg. Root possesses anti-leukaemic activity," *Chemistry Central Journal*, vol. 7, no. 1, article 157, 2013.
- [16] Y.-H. Lan, J.-H. Chiang, W.-W. Huang et al., "Activations of both extrinsic and intrinsic pathways in HCT 116 human colorectal cancer cells contribute to apoptosis through p53-mediated ATM/Fas signaling by *Emilia sonchifolia* extract, a folklore medicinal plant," *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 178178, 13 pages, 2012.
- [17] T.-J. S. A. Tajudin, N. Mat, A. B. Siti-Aishah, A. A. M. Yusran, A. Alwi, and A. M. Ali, "Cytotoxicity, antiproliferative effects, and apoptosis induction of methanolic extract of *Cynometra cauliflora* linn. Whole fruit on human promyelocytic leukemia HL-60 cells," *Evidence-based Complementary and Alternative Medicine*, vol. 2012, Article ID 127373, 6 pages, 2012.
- [18] J. D. D. Tamokou, J. R. Chouna, E. Fischer-Fodor et al., "Anticancer and antimicrobial activities of some antioxidant-rich cameroonian medicinal plants," *PLoS ONE*, vol. 8, no. 2, Article ID e55880, 2013.
- [19] K. Priyadarshini and A. U. Keerthi, "Paclitaxel against cancer: a short review," *Medicinal Chemistry*, vol. 2, no. 7, pp. 139–141, 2012.
- [20] C. Long, "Swaziland's Flora—siSwati Names and Uses," 2005, <http://www.sntc.org.sz/flora/clusagelist.asp?uid=2&pg=46>.
- [21] D. G. Fowler, *Traditional Fever Remedies: A List of Zambian Plants*, 2006, http://www.giftsofhealth.org/ritam/news/Traditional_Fever_remedie1.doc.
- [22] G. Sethi, M. K. Shanmugam, L. Ramachandran, A. P. Kumar, and V. Tergaonkar, "Multifaceted link between cancer and inflammation," *Bioscience Reports*, vol. 32, no. 1, pp. 1–15, 2012.
- [23] R. T. Abraham and A. Weiss, "Jurkat T cells and development of the T-cell receptor signalling paradigm," *Nature Reviews Immunology*, vol. 4, no. 4, pp. 301–308, 2004.
- [24] G. Kelter, J. M. Schierholz, I. U. Fischer, and H.-H. Fiebig, "Cytotoxicity activity and absence of tumour growth stimulation of standardized mistletoe extracts in human tumour models *in vitro*," *Anticancer Research*, vol. 27, no. 1, pp. 223–234, 2007.
- [25] E. K. Hoffmann and I. H. Lambert, "Ion channels and transporters in the development of drug resistance in cancer cells," *Philosophical Transactions of the Royal Society B: Biological Sciences*, vol. 364, pp. 1–10, 2014.
- [26] P. Tambama, B. Abegaz, and S. Mukanganyama, "Antiproliferative activity of the isofuranonaphthoquinone isolated from *Bulbine frutescens* against jurkat T cells," *BioMed Research International*, vol. 2014, Article ID 752941, 14 pages, 2014.
- [27] M. L. Kwan, G. Block, S. Selvin, S. Month, and P. A. Buffler, "Food consumption by children and the risk of childhood acute leukemia," *American Journal of Epidemiology*, vol. 160, no. 11, pp. 1098–1107, 2004.
- [28] S. M. Al-Ghannam, H. H. Ahmed, N. Zein, and F. Zahran, "Antitumor activity of balanitoside extracted from *Balanites aegyptiaca* fruit," *Journal of Applied Pharmaceutical Science*, vol. 3, no. 7, pp. 179–191, 2013.
- [29] S. Nataru, Y. Pulicherla, and B. Gaddala, "A review on medicinal plants as a potential source for cancer," *International Journal of Pharmaceutical Sciences Review and Research*, vol. 26, no. 1, pp. 235–248, 2014.
- [30] E. J. Chung, S.-G. Hwang, P. Nguyen et al., "Regulation of leukemic cell adhesion, proliferation, and survival by β -catenin," *Blood*, vol. 100, no. 3, pp. 982–990, 2002.
- [31] B. Svejda, V. Aguiriano-Moser, S. Sturm et al., "Anticancer activity of novel plant extracts from *Trailliaedoxa gracilis* (W. W. Smith & Forrest) in human carcinoid KRJ-I cells," *Anticancer Research*, vol. 30, no. 1, pp. 55–64, 2010.
- [32] B. Comín-Anduix, L. G. Boros, S. Marin et al., "Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells," *Journal of Biological Chemistry*, vol. 277, no. 48, pp. 46408–46414, 2002.
- [33] F. Vahedi, M. F. Najafi, and K. Bozari, "Evaluation of inhibitory effect and apoptosis induction of *Zyzyphus Jujube* on tumor cell lines, an *in vitro* preliminary study," *Cytotechnology*, vol. 56, no. 2, pp. 105–111, 2008.
- [34] N. Traverso, R. Ricciarelli, M. Nitti et al., "Role of glutathione in cancer progression and chemoresistance," *Oxidative Medicine and Cellular Longevity*, vol. 2013, Article ID 972913, 10 pages, 2013.
- [35] P. Imming, C. Sinning, and A. Meyer, "Drugs, their targets and the nature and number of drug targets," *Nature Reviews Drug Discovery*, vol. 5, no. 10, pp. 821–834, 2006.
- [36] C. Syng-Ai, A. L. Kumari, and A. Khar, "Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2," *Molecular Cancer Therapeutics*, vol. 3, no. 9, pp. 1101–1108, 2004.
- [37] A. Russo, W. DeGraff, N. Friedman, and J. B. Mitchell, "Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs," *Cancer Research*, vol. 46, no. 6, pp. 2845–2848, 1986.
- [38] R. M. Zucker, K. B. Whittington, and D. L. Decal, "The effect of glutathione on HL-60 treated with dimethylsulfoxide, butyric acid or 12-O-tetradecanoylphorbol-13-acetate," *FEBS Letters*, vol. 155, no. 1, pp. 107–112, 1983.
- [39] A. Pandey and S. Tripathi, "Concept of standardization, extraction and pre-phytochemical screening strategies for herbal drug," *Journal of Pharmacognosy and Phytochemistry*, vol. 2, no. 5, pp. 115–119, 2014.
- [40] A.-K. Brust, H. K. Ulbrich, G. M. Seigel, N. Pfeiffer, and F. H. Grus, "Effects of cyclooxygenase inhibitors on apoptotic neuroretinal cells," *Biomarker Insights*, vol. 3, pp. 387–402, 2008.
- [41] M. Wink, M. L. Ashour, and M. Z. El-Readi, "Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of cancer cells and microbes to cytotoxic and antimicrobial agents," *Frontiers in Microbiology*, vol. 3, article 130, 15 pages, 2012.

- [42] T. J. Key, N. E. Allen, E. A. Spencer, and R. C. Travis, "The effect of diet on risk of cancer," *The Lancet*, vol. 360, no. 9336, pp. 861–868, 2002.
- [43] S. C. Smolinske, "Herbal product contamination and toxicity," *Journal of Pharmacy Practice*, vol. 18, no. 3, pp. 188–208, 2005.